Human cytomegalovirus (HCMV) is a member of the herpes virus family and is transmitted via direct contact in all areas of world. In Japanese population, seropositivity for HCMV is higher. 1) After primary infection, this virus causes latent infection in lineage-committed myeloid cells, including progenitors that give rise to granulocytes, macrophages, and dendritic cells.
There are currently several approved anti-HCMV drugs, ganciclovir (GCV), foscarnet, cidofovir, fomivirsen, and valganciclovir in U.S.A. [5] [6] [7] [8] [9] GCV is exclusively used for the treatment of HCMV in Japan. GCV suffers limitations, however, including toxic side effects (bone marrow toxicity and nephrotocixity) and poor bioavailability. In addition, GCVresistant virus mutants can emerge more likely since the compound acts upon HCMV-specific DNA polymerase. Thus, in order to overcome these disadvantages of GCV for treating HCMV infections, other promising drug candidates having activity against HCMV, and mechanism of action different from GCV are needed.
Combination therapy with synergistically active antiviral agents that target different viral replication stages may provide several advantages over single-agent treatment, such as greater potency, superior clinical efficacy, reduction of the drug dosages needed, reduction of toxicity and side effects, reduction of the emergence of drug-resistant mutants, and greater cost-effectiveness. Several reports address the anti-HCMV activity of drug combinations. Combinations of GCV with human interferons, a polyamine synthesis inhibitor, foscarnet, 4,6-dibenzamidopyrazolo [3,4-d] pyrimidine, or a ribonucleotide reductase inhibitor were synergistic for HCMV replication. [10] [11] [12] [13] [14] We recently reported on a novel antiviral chromene derivative (1) (Chart 1).
15) The compound is derived from the plastoquinones isolated from the brown alga, Sargassum micracanthum, and shows potent and selective inhibition of HCMV replication in vitro. Among the chromene-related compounds, calanolide A containing the ring of chromene has reported to be an anti-human immunodeficiency virus (HIV) compound isolated from a tropical tree, Calophyllum lanigerum, and to function as an HIV-1-specific reverse transcriptase inhibitor. 16, 17) There has been so far no report on anti-HCMV action of chromenes. In the present study, we first elucidated the anti-HCMV target(s) of 1 under the various experimental conditions. Based on the findings that the compound inhibited HCMV replication in a different manner from that of GCV, we also evaluated combination therapy to determine whether the combined use of 1 and GCV reduced HCMV replication additively or synergistically in an in vitro situation.
MATERIALS AND METHODS

Materials
The compound 1 was prepared as described previously. 15) GCV was purchased from Syntex (Palo Alto, CA, U.S.A.).
Cell and Virus Human embryonic lung fibroblast (MRC-5) cells were grown in Eagle's minimum essential medium (MEM) (Nissui Pharmaceutical, Tokyo) supplemented with 5% fetal bovine serum (FBS). Stock human cytomegalovirus (HCMV) Towne strain, which is one of the common laboratory strains, was prepared by infecting MRC-5 cells at approximately 0.02 plaque-forming units (PFU) per cell.
Time-of-Addition Experiments MRC-5 cells in 48-well plates were infected with HCMV at 0.5 PFU per cell. At the indicated time points postinfection (p.i.), media were replaced with fresh media or media containing 1 (1, 10 mM) or GCV (10 mM) plus 0.5% methylcellulose (MC) and 5% FBS. After incubation at 37°C for 168 h, plates were stored at Ϫ80°C. They were subsequently thawed, and virus titer in each well was determined by plaque assay in 24-well plates as described previously. 18) Inhibitory effects of the compounds on HCMV replication were calculated as a percentage of reduction in titer in the presence of each compound at each time point compared to the titer obtained in the absence of compound. Data are presented as the mean triplicate results for each compound at each time point.
Inhibition of Virus Adsorption to Host Cells Infectious center assay was used for determining the effect of 1 on HCMV binding to cells. Briefly, HCMV (1 PFU/cell), MRC-5 cell suspension (1ϫ10 5 cells/ml) and 1 were cooled on ice for 2 h before mixing at 4°C. After 1-h incubation at 4°C, the cell suspensions were washed with ice-cold phosphate buffered saline (PBS) to remove unbound viruses and free compound. The cell pellets were diluted 100-or 1000-fold with ice-cold PBS and immediately added to MRC-5 cell monolayers in 12-well plates to be plaque-assayed as described above.
Penetration Inhibition Test MRC-5 cell monolayers in 12-well plates pre-cooled for 2 h on ice were infected with HCMV (approximately 100 PFU/well) at 4°C for 1 h. After washing three times with ice-cold PBS, cell monolayers were incubated at 37°C in the media containing 1. At 0, 0.5, 1, 2, 3, 6, 10 and 24 h after temperature shift to 37°C, the cell monolayers were treated with 40 mM citrate buffer (pH 3.0) for 1 min to inactivate unpenetrated viruses, and overlaid with media containing 0.5% MC and 5% FBS to be plaqueassayed.
Virucidal Assay To determine the effect of 1 on direct inactivation of virus particles, HCMV (200 PFU/100 ml) was treated with an equal volume of 1 at 37°C. After 0, 0.5, 1, 1.5 or 3 h, an aliquot of the mixture was added to MRC-5 cell monolayers in 24-well plates for 1 h at room temperature. The cell monolayers were overlaid with media containing 0.5% MC and 5% FBS to be plaque-assayed.
Interaction between 1 and GCV After infection of MRC-5 cells in 48-well plates with HCMV at 0.1 PFU per cell, each compound at different concentrations used alone or in combination was added to the plates. At 5 d of incubation at 37°C, the cell cultures were subjected to plaque yield reduction assay. The interaction between GCV and 1 was evaluated by isobologram 19) in which the x and y axes showed the ratio of the concentrations of 1 and 50% inhibitory concentrations (IC 50 s) of 1, and 50% fractional inhibitory concentrations (FIC 50 s) of GCV, respectively.
Statistics Values were expressed as the meanϮstandard deviation of the mean (S.D.) of triplicate assays. Statistical evaluation of the results was performed by one-way analysis of variance (ANOVA) followed by Dunnett's test. A probability value less than 0.05 was regarded as being statistically significant.
RESULTS
Effect of Time of Addition of 1 on HCMV Infectivity
In attempts to determine the antiviral target of 1 against HCMV replication and compare its target with that of GCV, time-of-addition experiments were performed. Each compound was added simultaneously or at 6, 11, 24, 30, 35, 48, 54, 59, 72, 78, 83, 96, 102, 107 and 120 h after exposure of cells to virus at a high multiplicity of infection (MOI) of 0.5. At 168 h p.i., virus yields were determined. As shown in Fig.  1 , GCV reduced markedly virus yield when added by 59 h p.i., and then produced less reduction in virus yield when added at 72 h p.i. or later. On the other hand, 10 mM of 1 caused a significant reduction in virus yield comparable to GCV effect when added by 11 h p.i. However, the compound was less effective as compared with its addition immediately after viral infection when added at 24 h p.i. or later.
Effect of 1 on Virus Adsorption and Entry From the time-of-addition experiments mentioned above, it was suggested that the most sensitive stage(s) of HCMV replication to 1 might be early events including virus attachment to and penetration into host cells. Thus, the inhibition of virus adsorption by 1 was confirmed by evaluating directly the number of cells binding the virus particles in the presence of the compound using infectious center assay. As shown in Fig. 2 , virus adsorption to cells at 4°C was significantly inhibited (pϽ0.001) by the treatment with 0.2 mM of 1, the concentration showing around the 50% inhibitory concentration. The inhibitory effect was concentration-dependent.
The possible effect of 1 on a subsequent stage of HCMV replication, virus internalization, was studied. Virus was adsorbed at 4°C in the absence of 1 without penetration into cells as confirmed by plaque assay, and then the temperature was raised to 37°C to allow the bound virus to penetration either in the absence or presence of the compound. The kinetics of HCMV penetration was seen in Fig. 3 . The compound showed significant concentration-dependent inhibition of virus penetration by 6 h of incubation, but no significant prevention of HCMV from penetration at 10 h or later.
Virucidal Action of 1 on Virus Particles As virus yield was significantly reduced even by the addition of higher concentration of 1 at 96 h p.i. or later (Fig. 1) , when mature progeny viruses should be released from cells, 20) the possibility that the compound acted directly on the virus particles to inactivate was investigated. Preincubation of HCMV with 1 resulted in time-and concentration-dependent reduction of remaining infectivity as shown in Fig. 4 . For example, longer exposure for 1.5 or 3 h caused the reduction of virus infectivity to 81 or 73% at 0.2 mM, to 69 or 60% at 1 mM, or, to 38 or 21% at 10 mM of the compound, respectively.
Effect of 1 Combined with GCV on HCMV Yield Because 1 and GCV was shown to act at different stages of the virus replication cycle as shown in the time-of-addition experiments, it was determined whether the combination of the two compounds reduced HCMV replication synergistically in an in vitro system. We tested five or seven different concentrations of GCV (0.01-0.5 mM) or 1 (0.01-0.2 mM), respectively, shown by individual dose response curves to give less than 50% reduction of the virus yield. 0.05-0.2 mM of 1 combined synergistically with GCV (0.01-0.5 mM) to reduce HCMV yield. The chromene derivative at 0.01 mM was additive with GCV. The 0.05-0.1 mM concentrations of GCV showed almost no antiviral effect by itself, but when combined with the 0.05 mM or higher concentrations of 1 the Samples of HCMV containing 100 PFU were incubated at 37°C for 0 to 3 h with 0.2, 1 or 10 mM of 1, and remaining infectivity was determined by plaque assay. ᭹, No drug control; ᭡, 1 (0.2 mM); , 1 (1 mM); ᭜, 1 (10 mM). Results are expressed as 100ϫ1-treated virus titer/control virus titer (the mean of triplicate assaysϮS.D.). * Significantly different from no drug control (pϽ0.05), * * significantly different from no drug control (pϽ0.01), * * * significantly different from no drug control (pϽ0.001).
virus was markedly reduced depending on the concentrations of the compounds. The analysis of the results by isobologram is presented in Fig. 5 .
DISCUSSION
In recent years, several classes of sulfated polysaccharides isolated from algae have been reported to have anti-HCMV activity. [21] [22] [23] [24] [25] However, no small molecule has been isolated as an anti-HCMV compound. Thus, this is the first report on the selective anti-HCMV action of a small molecule from algae.
For the determination of the antiviral target of 1, the timeof-addition study is especially diagnostic. HCMV DNA replication begins at approximately 16 h p.i. and peaks at 60 to 80 h p.i. followed by releasing of mature progeny viruses from cells over a 24-to 48-h period. 20, 26) As expected, GCV, a viral DNA polymerase inhibitor, exerted potent inhibitory effect on HCMV replication when added by around 60 h p.i. when viral DNA replication might peak. In contrast, 1 acted early in the replication, losing its effectiveness much earlier than GCV.
Mode of action studies are consistent with 1 having a main effect on the early events of virus replication cycle including virus adsorption and penetration as indicated by time-of-addition experiments. Adsorption of HCMV to host cell surface is likely mediated by the envelope glycoprotein gB, which binds to a poorly characterized receptor present on the surface of host cells. [27] [28] [29] Virus penetration following adsorption to cells is mediated by fusion of the virion envelope and the cell surface in a pH-independent manner.
30) The chromene derivative interferes effectively with the adsorption of HCMV to cell surface, and to a lesser extent, delays the internalization of virus, although, at present, it is not elucidated that with which site of viral or cellular components the compound may interact. Virucidal effect of 1 could also attribute to its antiviral action as this compound was able to inactivate viral particles at concentrations near the 50% inhibitory concentration.
Our results show that combination treatment with 1 and GCV markedly reduced HCMV yields in cells in comparison to the yield obtained after treatment with either single compound. In general, synergistic activities of compounds can be anticipated when two agents have unrelated modes of action. GCV is a potent inhibitor of HCMV DNA polymerase, whereas 1 exerts different effects as shown in the present study. Thus, the synergistic effect could be explained by inhibition of different steps in the viral replication cycle: HCMV binding to the target cells and virus inactivation, and intracellular synthesis of virus DNA. Combination therapy with reduced GCV dose may provide a means to treat HCMV infectious diseases while reducing drug toxicity and drug-resistant mutants.
In conclusion, we have shown the antiviral targets of 1 and the synergistic action of this compound with GCV for HCMV replication. Its virucidal and binding-inhibitory activities clearly different from GCV may offer advantages in its onward development. 
